Geode Capital Management Portfolio holdings
Geode Capital Management, founded in 2001 and based in Boston, Massachusetts, is a prominent institutional asset management firm known for its expertise in low-cost, systematic index investing. Originally established to manage internal index funds for Fidelity Investments, Geode became an independent entity while retaining a close relationship with Fidelity, focusing on passive investment strategies that track major market indices. The firm oversees hundreds of billions in assets, offering a range of mutual funds and separately managed accounts primarily for institutional clients, such as pension funds and endowments, with an emphasis on minimizing costs and maximizing efficiency. Geode’s disciplined, quantitative approach and avoidance of active management have made it a key player in the rise of index-based investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$524M |
| 2 |
Meta Platforms (Facebook)
META
|
+$458M |
| 3 |
Otis Worldwide
OTIS
|
+$345M |
| 4 |
T-Mobile US
TMUS
|
+$307M |
| 5 |
AbbVie
ABBV
|
+$280M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$878M |
| 2 |
RTN
Raytheon Company
RTN
|
+$537M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$435M |
| 4 |
Apple
AAPL
|
+$389M |
| 5 |
Accenture
ACN
|
+$216M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.72% |
| 2 | Healthcare | 14.52% |
| 3 | Financials | 12.98% |
| 4 | Consumer Discretionary | 10.98% |
| 5 | Communication Services | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1901
BioCryst Pharmaceuticals
BCRX
$2.38B
| $10.5M | ﹤0.01% |
2,210,753
+7,075
| +0.3% | +$28.3K |
|
|
PFC
1902
DELISTED
Premier Financial Corp. Common Stock
PFC
| $10.5M | ﹤0.01% |
592,452
+280
| +0% | +$4.53K |
|
1903
The Greenbrier Companies
GBX
$1.51B
| $10.5M | ﹤0.01% |
459,740
+3,010
| +0.7% | +$58.5K |
|
1904
Orthofix Medical
OFIX
$420M
| $10.4M | ﹤0.01% |
325,560
+10,198
| +3% | +$338K |
|
1905
ATN International
ATNI
$466M
| $10.4M | ﹤0.01% |
171,879
+4,166
| +2% | +$250K |
|
1906
Assembly Biosciences
ASMB
$523M
| $10.4M | ﹤0.01% |
37,150
+2,666
| +8% | +$622K |
|
|
PETQ
1907
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $10.3M | ﹤0.01% |
296,272
-2,948
| -1% | -$82.7K |
|
1908
Standex International
SXI
$4.04B
| $10.3M | ﹤0.01% |
178,243
+3,042
| +2% | +$154K |
|
1909
Liberty Media Series A
FWONA
$22.9B
| $10.3M | ﹤0.01% |
366,927
+17,394
| +5% | +$484K |
|
|
RPT
1910
DELISTED
RPT Realty Common Shares of Beneficial Interest (MD)
RPT
| $10.2M | ﹤0.01% |
1,466,700
+26,981
| +2% | +$172K |
|
1911
AstraZeneca
AZN
$249B
| $10.2M | ﹤0.01% |
96,246
-6,725
| -7% | -$695K |
|
|
GOOD
1912
Gladstone Commercial Corp
GOOD
$627M
| $10.1M | ﹤0.01% |
541,212
+33,978
| +7% | +$557K |
|
1913
Dine Brands
DIN
$446M
| $10.1M | ﹤0.01% |
240,862
+6,359
| +3% | +$257K |
|
1914
Magnolia Oil & Gas
MGY
$5.88B
| $10.1M | ﹤0.01% |
1,672,022
+244,286
| +17% | +$1.33M |
|
1915
RadNet
RDNT
$5.28B
| $10.1M | ﹤0.01% |
638,469
+23,303
| +4% | +$337K |
|
1916
CNA Financial
CNA
$14.2B
| $10.1M | ﹤0.01% |
314,334
-9,508
| -3% | -$293K |
|
1917
Artivion
AORT
$1.32B
| $10.1M | ﹤0.01% |
524,830
-789
| -0.2% | -$16.7K |
|
1918
Johnson Outdoors
JOUT
$500M
| $10M | ﹤0.01% |
110,127
+3,493
| +3% | +$250K |
|
|
FSP
1919
Franklin Street Properties
FSP
$46.6M
| $10M | ﹤0.01% |
1,966,864
+24,523
| +1% | +$130K |
|
|
HA
1920
DELISTED
Hawaiian Holdings, Inc.
HA
| $9.98M | ﹤0.01% |
711,127
+26,701
| +4% | +$364K |
|
|
MAGN
1921
Magnera Corp
MAGN
$447M
| $9.97M | ﹤0.01% |
47,780
+837
| +2% | +$159K |
|
|
SWTX
1922
DELISTED
SpringWorks Therapeutics
SWTX
| $9.96M | ﹤0.01% |
237,224
+76,611
| +48% | +$2.73M |
|
|
DLPH
1923
DELISTED
Delphi Technologies PLC Ordinary Shares
DLPH
| $9.95M | ﹤0.01% |
700,130
-1,948
| -0.3% | -$21.8K |
|
1924
Arcturus Therapeutics
ARCT
$171M
| $9.92M | ﹤0.01% |
212,201
+123,714
| +140% | +$4.26M |
|
1925
1st Source
SRCE
$2.15B
| $9.89M | ﹤0.01% |
278,016
+20,069
| +8% | +$665K |
|
Similar funds
Geode Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Geode Capital Management held 4,219 positions worth $467B, up 22% from $384B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Geode Capital Management's Q2 2020 filing shows 118 new, 2,550 increased, 1,055 reduced and 119 closed positions. Its largest new stake was Otis Worldwide: 6,650,358 shares worth $377M. The largest sale was Allergan plc, an estimated $878M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 22% a quarter earlier, followed by Healthcare and Financials.
- Geode Capital Management's largest Q2 2020 buy was Otis Worldwide: 6,650,358 shares worth $377M.
- Geode Capital Management added most to Amazon in Q2 2020, an estimated $524M increase.
- Geode Capital Management's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $435M.
- Geode Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $878M.
- Geode Capital Management's ten largest holdings make up 23% of its $467B portfolio in Q2 2020.
- Geode Capital Management opened 118 new positions and closed 119 in Q2 2020.
- Geode Capital Management's portfolio value rose 22% quarter-over-quarter to $467B.
Based on Geode Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.